Life Science Recruitment

"OpenAI will add 250 new roles across GTM (go to market / sales), engineering, user operations, human resources, finance, privacy, legal, corpsec and workplace. "

OpenAI announces new EU HQ and 250 additional jobs in Ireland OpenAI will create 250 jobs and establish its new EU headquarters in Dublin, further expanding its Irish operations.

Collaboration continues to fuel innovation in advanced therapies. EpilepsyGTx and ClearPoint Neuro have partnered to support a first-in-human gene therapy trial for epilepsy. Another exciting example of how collaboration is advancing treatments for neurological diseases.

EpilepsyGTx and ClearPoint Neuro join forces on targeted therapy - PharmaTimes Partnership to support first‑in‑human trial of EPY201 in epilepsy

A significant step forward in global health. Takeda's QDENGA has become the first dengue vaccine approved in India, marking an important step in tackling one of the world's fastest-growing mosquito-borne diseases. This approval highlights the continued impact of pharmaceutical innovation in improving public health and expanding access to life-saving vaccines.

Japanese drugmaker Takeda's Qdenga becomes first dengue vaccine approved in India Takeda Pharmaceutical's dengue vaccine Qdenga has been approved by India's drug regulator, making it the first such vaccine to be cleared in the country, the Japanese drugmaker's ​India unit said on Monday.

Positive news for patients living with IgA nephropathy. The FDA has granted full approval to Novartis' Fabhalta, marking another important advancement in kidney disease treatment. The decision reflects continued innovation in nephrology and highlights the strength of today's pharmaceutical pipeline.

Novartis gains full FDA nod for Fabhalta in kidney disorder IgAN With two approved medicines to treat primary immunoglobulin A nephropathy (IgAN) and a third therapy in phase 3 testing, Novartis is on its way to cornering the market for the indication. | The FDA has converted its accelerated approval for Novartis' Fabhalta into a full blessing to treat patients w...

IDA Ireland announced it secured 190 investments in the first half of 2026, supporting more than 10,400 approved jobs. The report highlights significant investment across life sciences, including Novo Nordisk's Athlone expansion, alongside continued investment in AI and advanced manufacturing.

IDA Ireland reports continued strong investment momentum in H1 2026 in midst of increasing competitive FDI landscape IDA Ireland Secures 190 Investments in H1 2026

Health-tech Dedalus opens new Irish HQ as part of €10m push!

Health-tech Dedalus opens new Irish HQ as part of €10m push Global health-tech Dedalus is continuing to build in Ireland by establishing a new Irish headquarters in Dublin’s Northwood Business Park.

The Irish Government has announced a €460 million investment to establish seven new Research Ireland "Rinn" Centres covering Advanced Therapies, Medical Devices, Pharma & Biopharma, Artificial Intelligence, Energy, Quantum and Semiconductors. The programme will support more than 570 research positions, over 800 PhD researchers and collaboration across 17 Irish research organisations over eight years. The initiative is designed to strengthen Ireland's research ecosystem and improve commercialisation opportunities.

Government announces €460 million investment for seven new ‘Rinn’ Research Ireland centres | Research Ireland As part of this announcement, an enhanced national research network, Rinn*, has been launched, under which each of the seven new Rinn centres will operate over the next eight years. This unified network reflects the step change in the scale and breadth of collaboration, governance, and funding, supp...

Irish developer of malaria vaccine wins European Inventor Award 2026!

Irish developer of malaria vaccine wins European Inventor Award Adrian Hill is the recipient of the European Inventor Award 2026 in the research category for his work developing a malaria vaccine

"Ireland's Biopharma Exports Hit €99.9 Billion - While Cutting Carbon Emissions by 30%"

Ireland's Biopharma Exports Hit €99.9 Billion — While Cutting Carbon Emissions by 30% — Health Pulse Irish pharmaceutical exports reached €99.9 billion in 2024 while electricity-related carbon emissions fell by 30.5%. Inside the life sciences story reshaping Ireland's biopharma sector.

Myricx Bio to be acquired by Novartis.

Novartis to acquire UK-based Myricx Bio for $1.5 billion Swiss drugmaker Novartis said today it had agreed to pay up to $1.5 billion for UK-based biotechnology firm Myricx Bio in a deal expected to close in the second half of 2026.